NCT03083561View on ClinicalTrials.gov

A Study of LY3337641 in Japanese and Caucasian Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

May 25, 2017

Study Completion Date

May 25, 2017

Conditions
Healthy
Interventions
DRUG

LY3337641

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

90630

WCCT Global, Cypress

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03083561 - A Study of LY3337641 in Japanese and Caucasian Healthy Participants | Biotech Hunter | Biotech Hunter